Evidence map›Paper›PMID 34530759›Full record

ArticleBMC cancer2021

Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.

A Hasenburg, D Eichkorn, F Vosshagen, E Obermayr, A Geroldinger, R Zeillinger, M Bossart

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01763125 (Establishment of a Blood Sample Bank in the Field of Gynaecological Oncology.), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01763125 recruitingnot on this map

Establishment of a Blood Sample Bank in the Field of Gynaecological Oncology.

TypeobservationalSponsorMedical University of ViennaRan2003 to 2026Enrolled10,000ConditionsOvarian Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Neoplasms of the Female GenitaliaArmsBlood collection
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Molecular Biomarkers for the Early Detection of Ovarian Cancer.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

A Hasenburg *Department of Obstetrics and Gynecology, University Medical Center, Mainz, Germany.
D Eichkorn *Department of Obstetrics and Gynecology, Schwarzwald-Baar Clinics, Villingen-Schwenningen, Germany.
F VosshagenDepartment of Anesthesiology, Ortenau Clinics, Lahr-Ettenheim, Germany.
E ObermayrDepartment of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
A GeroldingerSection for Clinical Biometrics, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
R ZeillingerDepartment of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
M BossartDepartment of Obstetrics and Gynecology, University Medical Center, Freiburg, Germany. Michaela.Bossart@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0003-3218-912X
Medical University of Vienna · ATJohannes Gutenberg University Mainz · DEOrtenau Klinikum · DESchwarzwald-Baar Klinikum · DEStatistics Austria · ATUniversity Medical Center Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTrial on five plasma biomarkers (CA125, HE4, OPN, leptin, prolactin) and their possible role in differentiating benign from malignant ovarian tumors.

methodsIn this unicentric prospective trial preoperative blood samples of 43 women with ovarian masses determined for ovarian surgery were analyzed. 25 patients had pathologically confirmed benign, 18 malignant ovarian tumors. Blood plasma was analyzed for CA125, HE4, OPN, leptin, prolactin and MIF by multiplex immunoassay analysis. Each single protein and a logistical regression model including all the listed proteins were tested as preoperative predictive marker for suspect ovarian masses.

resultsPlasma CA125 was confirmed as a highly accurate tumor marker in ovarian cancer. HE4, OPN, leptin and prolactin plasma levels differed significantly between benign and malignant ovarian masses. With a logistical regression model a formula including CA125, HE4, OPN, leptin and prolactin was developed to predict malignant ovarian tumors. With a discriminatory AUC of 0.96 it showed to be a highly sensitive and specific diagnostic test for a malignant ovarian tumor.

conclusionsThe calculated formula with the combination of CA125, HE4, OPN, leptin and prolactin plasma levels surpasses each single marker in its diagnostic value to discriminate between benign and malignant ovarian tumors. The formula, applied to our patient population was highly accurate but should be validated in a larger cohort.

trial registrationClinical Trials.gov under NCT01763125 , registered Jan. 8, 2013.

Indexed as

Early Detection of CancerAdultAgedAged, 80 and overArea Under CurveBiomarkers, TumorCA-125 AntigenCarcinoma, Ovarian EpithelialFemaleHumansLeptinLogistic ModelsMiddle AgedOsteopontinOvarian NeoplasmsProlactinBiomarkers, TumorCA-125 AntigenLeptinOsteopontinProlactinWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanBiomarkerCA125Liquid biopsyOvarian cancerProtein panel

Identifiers

PMID34530759
PMCPMC8447799
OpenAlexW3200589897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.